Genetic polymorphisms associated with blood concentration of lycopene
Patrick Borel, Jean-Francois Landrier, Charles Desmarchelier

To cite this version:
Patrick Borel, Jean-Francois Landrier, Charles Desmarchelier. Genetic polymorphisms associated with blood concentration of lycopene. Tomatoes and lycopene in human nutrition and health, preventing chronic diseases, CRC Press, 2017. <hal-01603161>
2 Genetic Polymorphisms Associated with Blood Concentration of Lycopene

Patrick Borel, Jean-François Landrier, and Charles Desmarchelier

CONTENTS

2.1 Introduction ................................................................. 21
2.2 Lycopene Fate in the Gastrointestinal Lumen during Digestion ........ 23
2.3 Apical Uptake, Intracellular Metabolism, and Basolateral Secretion of Lycopene by Enterocytes ............................................. 24
2.4 Regulation of Lycopene Absorption and Cleavage .............................. 26
2.5 Postprandial Blood Transport of Newly Absorbed Lycopene from the Intestine to the Liver ................................................................. 26
2.6 Liver Metabolism and Blood Transport of Lycopene from the Liver to Extra-Hepatic Tissues ................................................................. 27
2.7 Lycopene Metabolism in Extra-Hepatic Tissues ..................................... 28
2.8 Physiological Regulation of Blood Lycopene Concentrations ................. 28
2.9 Genetic Variations Associated with Blood Lycopene Concentration ...... 29
  2.9.1 Genetic Variations Associated with Fasting Blood Lycopene Concentration ................................................................. 29
  2.9.2 Genetic Variations Associated with Blood Lycopene Response to Dietary Lycopene ................................................................. 30
2.10 Other Genetic Variations that Could Be Involved in the Blood Concentration of Lycopene ................................................................. 33
List of Abbreviations ........................................................................ 34
References ......................................................................................... 34

2.1 INTRODUCTION

Lycopene is a red pigment found mainly in tomatoes and tomato products. It belongs to the carotenoid family, which contains hundreds of molecules, and more specifically to the carotene class (i.e., non-oxygenated carotenoids). Lycopene is the carotenoid found at the highest concentration in the blood of Americans (mean 23.5–27.4 μg/dL serum) (Wei, Kim, and Boudreau 2001) and in some geographical regions in Europe,
for example, Ragusa and Naples in Italia (Al-Delaimy et al. 2004). The interest in this carotenoid has risen in the last decades because it has been suggested to have a protective role against the development of prostate cancer and cardiovascular diseases (Story et al. 2010; Mordente et al. 2011; Bohm 2012; Giovannucci 1999; Viuda-Martos et al. 2014; Biddle et al. 2015; Cheng et al. 2017). The mechanisms that could explain this protective role have yet to be fully elucidated but both in vitro and animal studies have allowed experts to suggest several hypotheses. First of all, since oxidative stress has been implicated in the etiology of these diseases, lycopene has been suggested to exert its protective effect through its antioxidant properties, which have been well characterized in vitro (Kelkel et al. 2011). Nevertheless, lycopene also exhibits biological activities independent of its antioxidant effects: it modulates inflammation (Gouranton et al. 2011; Marcotorchino et al. 2012; Fenni et al. 2017), reduces cholesterol absorption efficiency (Zou and Feng 2015) and there are several studies suggesting that its metabolic products also exert non-antioxidant biological effects (Mein, Lian, and Wang 2008; Gouranton et al. 2011; Aydemir et al. 2013; Gouranton et al. 2012).

Although it is likely that lycopene, together with its metabolites, has various biological effects in our body, its essentiality has not been demonstrated. Thus, it is not considered a nutrient (Hendrich et al. 1994) and there is no recommended dietary allowance for it. Nevertheless, lycopene isomers and lycopene metabolites are present in several organs, tissues, and in our blood. Blood lycopene concentration depends on several factors. The first is obviously the dietary intake of lycopene, as we are unable to synthesize it. The second depends on lycopene absorption efficiency, which is very variable because it depends on several dietary factors (Desmarchelier and Borel 2017) as well as on the ability of each individual to absorb it (Bohn et al. 2015b; Borel et al. 2017). The third is the metabolism of lycopene within the body. Indeed, it is assumed that, after absorption, lycopene is transported from the gut to the liver and then distributed to peripheral tissues. Furthermore, because it is assumed that a significant fraction of lycopene is stored in adipose tissue (Chung et al. 2009), we hypothesize that the higher the fat mass of an individual, the higher their ability to store lycopene in adipose tissue and the lower their blood concentration of lycopene. The fourth group of factors are host-related, e.g., age, gender, disease, and inflammation, which are listed in recent reviews (Desmarchelier and Borel 2017; Borel et al. 2017). Several mechanisms involved in lycopene absorption and metabolism are governed, directly or indirectly, by proteins. It is therefore assumed that genetic variations that modulate either the activity of the proteins encoded by the genes carrying these genetic variations, or their expression, can affect lycopene absorption and/or metabolism and thus blood and tissue concentrations of lycopene (Borel 2012; Desmarchelier and Borel 2017).

In order to list the genes whose genetic variations could be suspected to affect lycopene absorption and/or lycopene metabolism, it is necessary to describe in detail all the successive metabolic steps that allow lycopene to enter the body and reach the tissues via the blood. Thus, this review starts with a detailed description of the fate of lycopene in the human body, from the food matrix in which it is ingested to extra-hepatic tissues via its transit in the liver. This will allow us to identify candidate proteins, and thus candidate genes, that can carry genetic variations able to modulate blood lycopene concentration. This review then lists the genetic variations that have
been associated with fasting and postprandial blood lycopene concentrations. The review finishes by listing the points to focus on in the forthcoming years to improve our knowledge on the genetic variations that modulate blood lycopene concentration.

### 2.2 Lycopene Fate in the Gastrointestinal Lumen During Digestion

Lycopene is insoluble in water. Thus, although it can be ingested in very different food matrices, e.g., raw tomatoes, tomato paste, or watermelon, it is assumed to transfer, at least in part, from these matrices to lipid droplets of dietary fat emulsions that are present in the gastrointestinal lumen during digestion (Borel 2003; Reboul et al. 2006; Tyssandier et al. 2003; Borel et al. 2001). This transfer, as well as the transfer of lycopene to mixed micelles, is modulated by numerous factors, e.g., food matrix, food processing, or the presence of fibres or lipids. It is beyond the scope of this review to describe the current knowledge on all these factors, but dedicated reviews can be found elsewhere (Borel 2003; Desmarchelier and Borel 2017; Bohn et al. 2015). This transfer can be facilitated by gastric and pancreatic enzymes that

---

**FIGURE 2.1** Proteins involved, or hypothesized to be involved, in lycopene metabolism within the lumen of the upper gastrointestinal tract. LYC: lycopene; PL: pancreatic lipase. Proteins followed by a question mark have been hypothesized to be involved because lycopene is not soluble in water and thus non-micellarized lycopene might be associated with proteins. Question marks and dotted arrows denote that this is suspected to exist but there is as yet no evidence thereof.
participate in food digestion, i.e. proteases, amylases and lipases (Figure 2.1). The genes that encode these enzymes are thus the first candidates that might affect lycopene absorption and thus blood and tissue lycopene concentrations. Lycopene transferred to lipid droplets, as well as a fraction of lycopene that is still embedded in its food matrix, transfer to mixed micelles in the duodenum/jejunum. Again, this transfer is assumed to be facilitated by the action of the digestive enzymes (Tyssandier, Lyan, and Borel 2001). Mixed micelles transport lycopene to the apical side of the enterocyte, where it is taken up via both passive diffusion and facilitated transport. Finally, we hypothesize that some lycopene might also associate with protein(s) or peptide(s) that also transport lycopene to the enterocyte.

2.3 APICAL UPTAKE, INTRACELLULAR METABOLISM, AND BASOLATERAL SECRETION OF LYCOPENE BY ENTEROCYTES

The mechanism by which micellarized lycopene crosses the apical membrane of the enterocyte is still not accurately known. Nevertheless, studies performed in the last decade have suggested that, contrary to what was previously assumed, lycopene uptake by the enterocyte is not only passive. This is supported by the possible saturation of absorptive mechanisms (Diwadkar-Navsariwala et al. 2003) and by the fact that several proteins, located in the apical membrane of the intestinal cell, have been involved
in lycopene uptake (Figure 2.2). These proteins are scavenger class B type I (SR-BI) (During, Dawson, and Harrison 2005; Moussa et al. 2008), which are encoded by SCARB1, CD36 molecule (CD36),—although its involvement has been demonstrated only in adipocyte (Moussa et al. 2011)—and NPC1 such as intracellular cholesterol transporter 1 (NPC1L1)—although there is conflicting data on its involvement because one study has suggested it (During, Dawson, and Harrison 2005) while another study has not (Moussa et al. 2008). It is not known whether these proteins have a direct or an indirect effect on lycopene uptake. Indeed, recent results suggest that they might indirectly modulate the apical to intracellular flux of lycopene by modulating the synthesis rate of chylomicrons (Buttet et al. 2014; Briand et al. 2016) in which lycopene is incorporated. Finally, if some lycopene is transported to the apical membrane bound to protein(s), it is not known whether it is absorbed and, if so, what is the mechanism.

After having crossed the apical membrane, lycopene must cross the polarized intestinal cell to be secreted at its basolateral side. Nothing is known about the mechanism involved but it is assumed that it compulsorily implicates proteins because lycopene is insoluble in water. Candidate proteins have been suggested (Reboul and Borel 2011). The first group are the proteins involved in the apical uptake of lycopene that display an intracellular cycle between the apical membrane and the cellular organelles. This is the case of all the above-mentioned proteins, i.e., NPC1L1, CD36, and SR-BI. Indeed, NPC1L1 has been observed in endosomes, perinuclear regions, lysosomes, and mitochondria. CD36 has been detected in the Golgi apparatus. SR-BI has been found in cytoplasmic lipid droplets and in tubulovesicular membranes. We hypothesize that lycopene binds to these proteins, or to apical membrane lipid micro-domains containing these proteins, and follows their fate within the cell. The second group are intracellular enterocyte proteins that carry lipids with a broad specificity, e.g., fatty acid binding proteins (liver and intestinal FABPs, i.e., L- and I-FABP), which are both present in the intestine. The fact that a genetic association study has shown that a genetic variant in I-FABP was associated with fasting plasma lycopene concentrations (Borel et al. 2009) supports this hypothesis. The third group is composed of the enzymes responsible for carotenoid metabolism, i.e., beta-carotene oxygenase 1 (BCO1) (Lobo et al. 2012; Amengual et al. 2013) and beta-carotene oxygenase 2 (BCO2) (Hu et al. 2006). BCO1 is cytoplasmic (Lindqvist and Andersson 2002) and it is able to cleave lycopene (Dela Sena et al. 2013; Dela Sena et al. 2016) in the cytosol of mature enterocytes from the jejunum (Duszka et al. 1996). It is thus reasonable to suggest that it is also able to transport lycopene within the cell. Although BCO2 is able to cleave cis-isomers of lycopene (Hu et al. 2006), we suppose that its mitochondrial localization (Amengual et al. 2011) is not compatible with its involvement as an intracellular transporter of lycopene.

It is not known how all-trans lycopene is isomerized to cis-lycopene isomers in the enterocyte and whether there is a lycopene isomerase involved in this phenomenon, but it has been shown that there is a very efficient isomerization of lycopene in the intestinal cell (Richelle et al. 2010; Ross et al. 2011; Richelle et al. 2012). This explains why, while we eat mostly all-trans lycopene, there are mostly cis-lycopene isomers in our blood and tissues (Stahl et al. 1992).

The secretion mechanism of lycopene at the basolateral side of the intestinal cell likely depends on its cleavage in the enterocyte. Indeed, it is assumed that the parent
molecules, i.e., the all-trans and cis isomers of lycopene, are incorporated in nascent chylomicrons (Borel et al. 1998), while lycopene metabolites, which are produced by BCO1 or BCO2 (Lindshield et al. 2008; Dela Sena et al. 2013; Dela Sena et al. 2016; Hu et al. 2006; Ford, Elsen, and Erdman 2013), are secreted in the portal blood. However, we suggest that some very hydrophobic lycopene metabolites, i.e., with log P > 5, might be incorporated in chylomicrons as well. The mechanisms responsible for the incorporation of lycopene in chylomicrons are barely known but it is assumed that they involve enzymes/apolipoproteins responsible for the assembly of chylomicrons, e.g., microsomal triglyceride transfer protein (MTP), apoA-IV, secretion associated Ras related GTPase 1B (SAR1B), and apoB48 (Hussain et al. 2005). It has also been suggested that the protein involved in HDL secretion, i.e., ATP-binding cassette, subfamily A, member 1 (ABCA1), might also be involved in lycopene secretion in intestinal HDL (Reboul and Borel 2011).

2.4 REGULATION OF LYCOPENE ABSORPTION AND CLEAVAGE

It is as yet unknown whether lycopene absorption and cleavage are regulated. However, the fact that SR-B1 is involved in lycopene absorption (During, Dawson, and Harrison 2005; Moussa et al. 2008) and that BCO1 is involved in its cleavage (Dela Sena et al. 2013), suggests that it could be regulated by vitamin A status. Indeed, it has been demonstrated that vitamin A status regulates β-carotene absorption and cleavage efficiency via a negative feedback loop that involves an intestinal transcription factor called intestine specific homeobox (ISX) (Lobo et al. 2013; Lobo et al. 2010). ISX acts as a repressor of SCARBI and BCO1 upon retinoic acid activation. When the intracellular concentration of retinoic acid drops, which is assumed to be the case when vitamin A intake is insufficient, ISX exerts less repressor activity towards SCARBI and BCO1 and consequently β-carotene uptake and conversion efficiency increase. This mechanism might regulate the absorption and the cleavage efficiencies of lycopene as well, although dedicated studies should be performed to verify this hypothesis.

2.5 POSTPRANDIAL BLOOD TRANSPORT OF NEWLY ABSORBED LYCOPENE FROM THE INTESTINE TO THE LIVER

As previously stated, newly absorbed lycopene is assumed to be secreted both as a mixture of all-trans and cis-isomers of the parent molecules in chylomicrons, and as lycopene metabolites in the portal blood. Concerning the second pathway, there is no information, but it can be suggested that the water-soluble metabolites of lycopene are solubilized in the portal blood and/or are incorporated in intestinal HDL and carried to the liver. Concerning the apo-B-dependent pathway, it is assumed that the all-trans and the cis isomers of lycopene are carried by chylomicrons to the liver, where they are taken up. Indeed, lycopene is apparently not significantly exchanged between lipoproteins (Romanchik, Morel, and Harrison 1995; Tyssandier et al. 2002) and thus it is assumed that it stays in the chylomicrons during their intravascular metabolism. However, these studies were performed with the all-trans isomer and it is possible that the cis-isomers are able to significantly transfer
Genetic Polymorphisms Associated with Blood Concentration of Lycopene

between lipoproteins or to transfer from lipoproteins to tissues during intravascular chylomicron metabolism (Zaripheh and Erdman 2005). Whatever the proportion of lycopene that is transferred to other lipoproteins or to tissues during chylomicron metabolism, it is assumed that the remaining fraction is taken up by the liver via the chylomicron-remnant receptors, i.e., the LDL-receptor (LDLR), the LDL-receptor related protein 1 (LRP1), and the heparan sulfate proteoglycans (HSPGs) (Dallinga-Thie et al. 2010).

2.6 LIVER METABOLISM AND BLOOD TRANSPORT OF LYCOPENE FROM THE LIVER TO EXTRA-HEPATIC TISSUES

Liver is the primary depot organ for lycopene (Mathews-Roth et al. 1990; Schmitz et al. 1991; Ferreira et al. 2000; Zaripheh et al. 2003; Korytko et al. 2003). Following chylomicron-remnant uptake by the liver, it is assumed that lycopene is released in hepatocytes (Figure 2.3). It is then assumed that it is transferred, by an unknown mechanism but that likely involves protein(s) (since lycopene is insoluble in the water environment of the cell), to the fat-storing cells (also called lipocytes), hepatic stellate cells, or Ito cells. Indeed, these cells, which are well known to store vitamin A (Borel and Desmarchelier 2017), are apparently also able to store lycopene (Teodoro

FIGURE 2.3 Proteins involved in the liver metabolism of lycopene. This figure shows current knowledge on the proteins involved in the liver metabolism of lycopene and in its distribution to peripheral tissues. Lycopene reaches the liver incorporated in chylomicron remnants following lycopene absorption. Lycopene is then mostly stored in hepatic stellate cells. The liver is assumed to be a hub of lycopene metabolism. Indeed, it is the main organ that stores lycopene and distributes it to the peripheral tissues. Question marks and dotted arrows denote that this is suspected to exist but there is as yet no evidence thereof.
et al. 2009). Again, it is not known how lycopene stored in these cells is mobilized, and which proteins are involved. Concerning its liver metabolism, it likely depends on lycopene isomerization. Indeed, the all-trans isomer is only cleaved by BCO1 (Lindshield et al. 2008; Dela Sena et al. 2013; Dela Sena et al. 2016), which is highly expressed in hepatic stellate cells (Shmarakov et al. 2010), while the 5-cis and 13-cis isomers are only cleaved by BCO2 (Hu et al. 2006; Ford, Elsen, and Erdman 2013). It is assumed that the fraction of lycopene that is not metabolized or stored in the liver is either secreted in the bile (Leo et al. 1995) or in the blood, mainly in VLDL. It is not known whether the liver also secretes lycopene metabolites in the blood. Because it is assumed that LDL, which originates from intravascular metabolism of VLDL, are responsible for the distribution of lycopene to peripheral tissues, it is hypothesized that only tissues that express the LDL-receptor can take up lycopene. However, it has been shown that CD36, which is able to bind oxidized LDL, is involved in adipose tissue uptake of lycopene (Moussa et al. 2008), and it cannot be excluded that a fraction of lycopene can reach some tissues during chylomicron metabolism (Zaripheh and Erdman 2005).

2.7 LYCOPENE METABOLISM IN EXTRA-HEPATIC TISSUES

The metabolism of lycopene in extra-hepatic tissues is barely known. It is out of the scope of this review to exhaustively list what is known in each tissue but it is necessary to talk about adipose tissue. Indeed, since it is assumed that a significant fraction of lycopene is stored in this tissue (Chung et al. 2009), we hypothesize that the ability of adipose tissue to store lycopene, or after storage to resecrete it, could have a significant impact on blood lycopene concentration.

2.8 PHYSIOLOGICAL REGULATION OF BLOOD Lycopene CONCENTRATIONS

The blood concentration of lycopene can significantly vary during the period that follows a meal rich in lycopene when compared to the fasting state. For example, it increased from about 460 to about 560 nmol/l after intake, by healthy adults, of a meal that provided 19 mg of lycopene in tomato paste (Borel et al. 2016). Thus, when talking about blood lycopene concentration, it is important to specify when its concentration is measured, i.e., in the fasting period or during the postprandial period. It is assumed that there is no direct regulation of blood lycopene concentration. In the fasting state about 75% of lycopene is transported in LDL (Romanchik, Morel, and Harrison 1995; Goulinet and Chapman 1997) but it is also found in VLDL and HDL. During the postprandial period, it is transported both in these lipoproteins and in chylomicrons (if a meal containing lycopene was ingested). Thus, we assume that blood concentration of lycopene mainly depends: 1) on the state at which the blood is collected, i.e., at fast or in the postprandial period, and when in the postprandial time; 2) on the amount of lycopene that is usually ingested by the subject, which is a key factor governing its LDL concentration; 3) on the amount of lycopene that was ingested in the meal that preceded blood sampling; 4) on the subject metabolism of
Genetic Polymorphisms Associated with Blood Concentration of Lycopene

lipoproteins in which lycopene is incorporated; and 5) on the ability of the subject to store/resecret lycopene in/from their adipose tissue, which in turn depends on their body fat mass and on the metabolism of lycopene in their adipose tissue. Thus, blood lycopene concentration is likely modulated by several proteins, the main ones being those that regulate LDL (García-Ríos et al. 2012) and chylomicron metabolism (Dallinga-Thie et al. 2010; Perez-Martínez et al. 2010; Desmarchelier et al. 2014).

2.9 GENETIC VARIATIONS ASSOCIATED WITH BLOOD LYPOPENE CONCENTRATION

Clinical trials have systematically reported a huge interindividual variability in blood and tissue lycopene response to lycopene intake (Stahl and Sies 1992; Bowen et al. 1993; Johnson et al. 1997; O’Neill and Thurnham 1998; Diwadkar-Navsariwala et al. 2003; Wang, Edwards, and Clevidence 2013; Forman et al. 2009; Gustin et al. 2004; Borel et al. 2015b). For example, the coefficient of variation of the postprandial chylomicron lycopene response measured in 33 healthy subjects after the intake of a test meal that provided 9.7 mg lycopene in 100 g of tomato puree was 70% (Borel et al. 2015b). Genetic variations between individuals have been suggested to explain, at least in part, this phenomenon (Borel 2012; Moran, Erdman, and Clinton 2013; Desmarchelier and Borel 2017; Bohn et al. 2017). It has even been suggested that ethnically related genetic variants can influence blood carotenoid concentration (Arab et al. 2011). The use of genome-wide association studies (GWAS) to identify genetic variations associated with diseases (van der Sijde, Ng, and Fu 2014) and various phenotypes is relatively recent. These studies usually require the recruitment of thousands of subjects and are thus very expensive. This explains why there are only three GWAS dedicated to identifying genetic variations associated with blood lycopene concentration (Ferrucci et al. 2009; Zubair et al. 2015; D’Adamo et al. 2016). This also explains why there is no GWAS dedicated to identifying genetic variations associated with lycopene bioavailability. Indeed, the measurement of this phenotype requires a postprandial study, which cannot be performed easily across thousands of volunteers. In fact, there is only one candidate gene association study (CGAS) dedicated to identifying genetic variations associated with this phenotype (Borel et al. 2015b).

2.9.1 GENETIC VARIATIONS ASSOCIATED WITH FASTING BLOOD LYPOPENE CONCENTRATION

The three GWAS dedicated to identifying genetic variations associated with fasting blood lycopene concentration (Ferrucci et al. 2009; Zubair et al. 2015; D’Adamo et al. 2016) have identified single nucleotide polymorphisms (SNPs) in or near five genes (Table 2.1). In alphabetical order: BCO1 (Ferrucci et al. 2009), dehydrogenase/reductase 2 (DHRS2) (Zubair et al. 2015), SCARB1 (Zubair et al. 2015; D’Adamo et al. 2016), SET domain containing lysine methyltransferase 7 (SETD7) (D’Adamo et al. 2016) and slit guidance ligand 3 (SLIT3) (Zubair et al. 2015). It should be reminded that GWAS do not make any assumption on the genes that can affect the studied
disease/phenotype and thus allow us to identify associations that were not expected to be involved in the studied disease/phenotype, in this case fasting blood lycopene concentration. This is the case for the associations found with SLIT3, STED7 and DHRS2. In fact, the associations with SLIT3 and SETD7 were not explained by the authors. SLIT3 serves as a molecular guidance cue in cellular migration, and SETD7 is one of the histone methyltransferases (HMTs) enzymes. Current knowledge on lycopene metabolism does not allow us to suggest a simple explanation of these associations. Concerning DHRS2, which encodes for an oxidoreductase, the authors only hypothesized that “it could be involved in lycopene metabolism.” Thus, further studies should confirm these associations and try to explain the role of these genes on blood lycopene concentration. The associations found with SCARB1 and BCO1 are easier to explain. SCARB1 encodes for SR-BI, which is involved in lycopene absorption and tissue uptake (During, Dawson, and Harrison 2005; Moussa et al. 2008) and BCO1 encodes for beta-carotene oxygenase 1, which is able to cleave lycopene (Dela Sena et al. 2013). The GWAS have thus confirmed the key role of these proteins/genes in lycopene metabolism.

Only two CGAS were dedicated to study associations between genetic variations in genes assumed to be involved in lycopene metabolism and fasting blood lycopene concentration (Borel et al. 2009; Borel et al. 2007) (Table 2.1). These studies focused on genes involved in lipid metabolism because lycopene is transported/stored in lipid structures in our body, e.g., lipoproteins or membranes, and it is thus assumed that its metabolism is closely related to that of lipids. These CGAS have found that SNPs in I-FABP, apoB and apoA-IV were associated with fasting blood lycopene concentration. These associations were not found in the GWAS. Thus, they likely play a minor role in this phenotype and they should be replicated in other studies. However, it should be reminded that GWAS usually lead to false negative associations, i.e., to the rejection of genetic variants that are actually associated with the studied disease/phenotype, because of the statistical stringency used in this approach.

2.9.2 Genetic Variations Associated with Blood Lycopene Response to Dietary Lycopene

Although the identification of genetic variations associated with fasting blood lycopene concentration is of interest to better understand lycopene metabolism, the application of the results to clinical practice or dietary recommendations is otherwise not straightforward. Indeed, the highest risk factor for developing low blood lycopene concentration is usually low lycopene intake. Nevertheless, since lycopene displays a huge interindividual variability in its bioavailability, which is partly due to genetic variants, the objective to increase blood lycopene concentration should rely on identifying tailored nutritional strategies, i.e., based on the assessment of the lycopene responder phenotype of a population/individual. For example, an individual, or a group of individuals, exhibiting low blood lycopene concentrations with high capacity to absorb lycopene could be advised to increase their intake of lycopene-rich foods to increase their lycopene status. Conversely, this dietary recommendation will likely fail in subjects who are low responders to dietary lycopene and who will need supplements very rich in lycopene to improve their lycopene status.
To our knowledge, there are only two studies dedicated to identifying genetic variations associated with blood lycopene response to dietary lycopene (Table 2.1). The first one examined the plasma lycopene response to consumption of lycopene-rich beverages for three weeks (Wang, Edwards, and Clevidence 2013). In that study, individual responsiveness was associated with genetic variants in BCO1. The second study was dedicated to identifying a combination of genetic variants associated with lycopene bioavailability, which was evaluated by the postprandial chylomicron lycopene response to a test meal that provided tomato puree as a source of lycopene (Borel et al. 2015b). This study showed that lycopene bioavailability was associated with a combination of 28 SNPs in or near 16 candidate genes (Table 2.1). Seven of these genes—ABCA1, lipoprotein lipase (LPL), insulin induced gene 2 (INSIG2), solute carrier, family 27, member 6 (SLC27A6), lipase C, hepatic type (LIPC), CD36, and APOB—had been associated with the postprandial chylomicron triacylglycerol response in the same group of subjects (Desmarchelier et al. 2014). This was not surprising as most newly absorbed lycopene is carried from the intestine to peripheral organs via chylomicrons, which are mainly composed of triacylglycerols. Nevertheless, four of these genes, i.e., ELOVL2, MTTP, ABCB1 and SOD2, were specifically and significantly associated with lycopene bioavailability. Possible explanations why these genes were associated with the lycopene bioavailability are discussed in the original paper (Borel et al. 2015a). In summary, ELOVL2 is known to catalyze the elongation of EPA (eicosapentaenoic acid) to DPA (docosapentaenoic acid) and DPA to DHA (docosahexaenoic acid). Although lycopene is not considered to be a substrate for this enzyme, the fact that SNPs in this gene were also associated with both lutein (Borel et al. 2014) and β-carotene bioavailability (Borel et al. 2015a) strongly suggest that ELOVL2 is involved, directly or indirectly, in carotenoid, and thus lycopene, metabolism. MTTP encodes for the microsomal triglyceride transfer protein, which is involved in the packaging of triacylglycerols within the chylomicrons. Its association with lycopene bioavailability is therefore not surprising, as lycopene is incorporated into chylomicrons in the enterocyte. ABCB1 encodes for the P-glycoprotein, an ATP-dependent drug efflux pump for xenobiotics with broad substrate specificity. Its association suggests that this protein may participate in lycopene net absorption, possibly by effluxing a fraction of uptaken lycopene back to the intestinal lumen. SOD2 is responsible for converting superoxide by-products to hydrogen peroxide and diatomic oxygen. It was hypothesized that, when this enzyme is not efficient, superoxide by-products are quenched by lycopene, leading to its degradation. Surprisingly, SNPs in genes assumed to be involved in lycopene absorption and metabolism were not associated with lycopene bioavailability. These SNPs were in SCARB1 and CD36, which encode for proteins involved in the cellular uptake of lycopene (During, Dawson, and Harrison 2005; Moussa et al. 2008; Moussa et al. 2011), and BCO1 and BCO2, which are able to cleave various isomers of lycopene. Several hypotheses have been suggested in the original paper to explain this lack of association (Borel et al. 2015b). It was first hypothesized that SNPs genotyped in these genes do not result in a functionally different phenotype with regards to lycopene bioavailability. It was also hypothesized that the association of SNPs in these genes was weaker than that of the SNPs in the selected partial least square model. It was finally hypothesized that some SNPs in these genes were not entered in the
# TABLE 2.1
Summary of SNPs Associated with Fasting Blood Lycopene Concentration or Blood Lycopene Response to Dietary Lycopene

<table>
<thead>
<tr>
<th>SNP</th>
<th>Global MAF</th>
<th>Nearest Gene</th>
<th>Trait</th>
<th>Reference</th>
<th>Study Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs6564851</td>
<td>0.476</td>
<td>BCO1</td>
<td>FB-LYC</td>
<td>(Ferrucci et al. 2009)</td>
<td>GWAS^a</td>
</tr>
<tr>
<td>rs74036811</td>
<td>0.020</td>
<td>DHRS2</td>
<td>FB-LYC</td>
<td>(Zubair et al. 2015)</td>
<td>GWAS^b</td>
</tr>
<tr>
<td>rs7680948</td>
<td>0.341</td>
<td>SETD7</td>
<td>FB-LYC</td>
<td>(D’Adamo et al. 2016)</td>
<td>GWAS</td>
</tr>
<tr>
<td>rs1672879</td>
<td>0.269</td>
<td>SCARB1</td>
<td>FB-LYC</td>
<td>(Zubair et al. 2015)</td>
<td>GWAS</td>
</tr>
<tr>
<td>rs11057841</td>
<td>0.179</td>
<td>SCARB1</td>
<td>FB-LYC</td>
<td>(D’Adamo et al. 2016)</td>
<td>GWAS^c</td>
</tr>
<tr>
<td>rs78219687</td>
<td>0.017</td>
<td>SLIT3</td>
<td>FB-LYC</td>
<td>(Zubair et al. 2015)</td>
<td>GWAS^d</td>
</tr>
<tr>
<td>APO A-IV-Ser347</td>
<td>0.025</td>
<td>APOAIV</td>
<td>FB-LYC</td>
<td>(Borel et al. 2007)</td>
<td>CGAS</td>
</tr>
<tr>
<td>Apo B -516</td>
<td>0.085</td>
<td>APOB</td>
<td>FB-LYC</td>
<td>(Borel et al. 2007)</td>
<td>CGAS</td>
</tr>
<tr>
<td>I-FABP-Thr</td>
<td>0.089</td>
<td>IFABP</td>
<td>FB-LYC</td>
<td>(Borel et al. 2009)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs12934922</td>
<td>0.357</td>
<td>BCO1</td>
<td>FB-LYC-R^e</td>
<td>(Wang, Edwards, and Clevidence 2013)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs7501331</td>
<td>0.213</td>
<td>BCO1</td>
<td>FB-LYC-R^e</td>
<td>(Wang, Edwards, and Clevidence 2013)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs1331924^e</td>
<td>0.245</td>
<td>ABCA1</td>
<td>LYC-B^d</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs2791952^e</td>
<td>0.140</td>
<td>ABCA1</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs3887137^e</td>
<td>0.123</td>
<td>ABCA1</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs4149299^e</td>
<td>0.082</td>
<td>ABCA1</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs4149316^e</td>
<td>0.122</td>
<td>ABCA1</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs10248420</td>
<td>0.347</td>
<td>ABCB1</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs10280101</td>
<td>0.145</td>
<td>ABCB1</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs1871744</td>
<td>0.499</td>
<td>ABCG2</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs1042031^e</td>
<td>0.153</td>
<td>APOB</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs4112274^e</td>
<td>0.224</td>
<td>CD36</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs3798709</td>
<td>0.252</td>
<td>ELOVL2</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs911196</td>
<td>0.252</td>
<td>ELOVL2</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs9468304</td>
<td>0.302</td>
<td>ELOVL2</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs17006621^e</td>
<td>0.172</td>
<td>INSSI2</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs2056983</td>
<td>0.117</td>
<td>ISX</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs12914035^e</td>
<td>0.096</td>
<td>LIPC</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs8035357^e</td>
<td>0.150</td>
<td>LIPC</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs17482753^e</td>
<td>0.088</td>
<td>LPL</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs7005359^e</td>
<td>0.298</td>
<td>LPL</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs7841189^e</td>
<td>0.148</td>
<td>LPL</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs1032355</td>
<td>0.251</td>
<td>MTTP</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs17029173</td>
<td>0.135</td>
<td>MTTP</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs745075</td>
<td>0.095</td>
<td>MTTP</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs17725246</td>
<td>0.254</td>
<td>NPC1L1</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs935933</td>
<td>0.139</td>
<td>PKD1L2</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
<tr>
<td>rs11197742</td>
<td>0.087</td>
<td>PNLIP</td>
<td>LYC-B</td>
<td>(Borel et al. 2015b)</td>
<td>CGAS</td>
</tr>
</tbody>
</table>

(Continued)
partial least square regression analysis because either they were not expressed on the BeadChips, or they were excluded from the analysis (for not following the Hardy-Weinberg equilibrium or because their genetic call rate was <95%). Nevertheless, only further studies will allow us to answer whether these genes are not key genes with regard to lycopene bioavailability, at least when it is evaluated by the method used in this paper, or whether this lack of associations is due to another hypothesis.

### 2.10 OTHER GENETIC VARIATIONS THAT COULD BE INVOLVED IN THE BLOOD CONCENTRATION OF LYCOPENE

The low number of available studies presented in the previous paragraphs highlights the tremendous work that remains to be done to identify all the genetic variations associated with blood lycopene concentration (Table 2.1). Furthermore, there is still no study dedicated to identifying genetic variations that could modulate lycopene concentration in different tissues. It should also be remembered that, although SNPs represent ≈90% of genetic polymorphisms, other genetic variations occur in DNA, e.g., copy number variants, insertion/deletion of some base pairs, and epigenetic modifications. A genetic score that would aim to predict lycopene concentration in blood and in different tissues should therefore consider all the genetic variations that can have a significant impact on these concentrations. Finally, association studies must be performed in different populations to be sure that the associations are not specific to some ethnic groups.
In summary, there is now enough evidence to state that blood, and likely tissue, lycopene concentration, and lycopene bioavailability, are partly modulated by genetic variations in several genes. However, a lot of work remains to be done to propose combinations of genetic variations (SNPs, but also other kinds of genetic variations) that will allow us to confidently predict the concentration of lycopene in the blood or in the tissue of an individual by knowing his genotype at these variations. Yet, the potential usefulness of this area of research is exciting regarding personalized nutrition. Finally, it is important to remember that genetics only represents one of the factors that affect lycopene concentration in blood and tissues, albeit stable over the lifespan, since other factors, such as lycopene dietary intake, and factors that affect lycopene bioavailability (e.g., cooking practice), also affect this status. Thus, a prediction of lycopene concentration in blood and in various tissues should also consider these variables.

LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCA1</td>
<td>(ATP-binding cassette, subfamily A, member 1)</td>
</tr>
<tr>
<td>ABCB1</td>
<td>(ATP-binding cassette, subfamily B (MDR/TAP), member 1)</td>
</tr>
<tr>
<td>BCO1</td>
<td>(β-carotene oxygenase 1)</td>
</tr>
<tr>
<td>BCO2</td>
<td>(β-carotene oxygenase 2)</td>
</tr>
<tr>
<td>CD36</td>
<td>(CD36 molecule)</td>
</tr>
<tr>
<td>DHRS2</td>
<td>(dehydrogenase/reductase 2)</td>
</tr>
<tr>
<td>ELOVL2</td>
<td>(ELOVL fatty acid elongase 2)</td>
</tr>
<tr>
<td>HSPGs</td>
<td>(heparan sulfate proteoglycans)</td>
</tr>
<tr>
<td>INSIG2</td>
<td>(insulin-induced gene 2)</td>
</tr>
<tr>
<td>ISX</td>
<td>(intestine specific homeobox)</td>
</tr>
<tr>
<td>LDLR</td>
<td>(LDL-receptor)</td>
</tr>
<tr>
<td>L-FABP</td>
<td>(liver-fatty acid binding protein)</td>
</tr>
<tr>
<td>LIPC</td>
<td>(lipase C, hepatic type)</td>
</tr>
<tr>
<td>LPL</td>
<td>(lipoprotein lipase)</td>
</tr>
<tr>
<td>LRP1</td>
<td>(LDL-receptor related protein 1)</td>
</tr>
<tr>
<td>MTTP</td>
<td>gene/MTP protein (microsomal triglyceride transfer protein)</td>
</tr>
<tr>
<td>SAR1B</td>
<td>(secretion associated Ras related GTPase 1B)</td>
</tr>
<tr>
<td>SCARB1</td>
<td>gene/SR-BI protein (scavenger receptor, class B, member 1)</td>
</tr>
<tr>
<td>SETD7</td>
<td>(SET domain containing lysine methyltransferase 7)</td>
</tr>
<tr>
<td>SLC27A6</td>
<td>(solute carrier, family 27, member 6)</td>
</tr>
<tr>
<td>SLIT3</td>
<td>(slit guidance ligand 3)</td>
</tr>
<tr>
<td>SNPs</td>
<td>(single nucleotide polymorphisms)</td>
</tr>
<tr>
<td>SOD2</td>
<td>(superoxide dismutase 2, mitochondrial).</td>
</tr>
</tbody>
</table>

REFERENCES


Genetic Polymorphisms Associated with Blood Concentration of Lycopene


Genetic Polymorphisms Associated with Blood Concentration of Lycopene


**Author Contributions:** P. Borel, C. Desmarchelier and J.F. Landrier have equally contributed to the writing of this review.

**Conflicts of Interest:** The authors declare no conflict of interest.